


## LISTING OF THE CLAIMS

1. (Currently Amended) A compound of formula (I):



wherein

$M^1$  is  $-CH_2-$ ;

$M^2$  is  $-NR^{24}-$ ;


one of  $R^1$  and  $R^2$  is selected from hydrogen or  $C_{1-6}$ alkyl and the other is selected from  $C_{1-6}$ alkyl;

~~$R^3$  is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl,  $C_{1-6}$ alkyl,  $C_{2-6}$ alkenyl,  $C_{2-6}$ alkynyl,  $C_{1-6}$ alkoxy,  $C_{1-6}$ alkanoyl,  $C_{1-6}$ alkanoyloxy,  $N$ -( $C_{1-6}$ alkyl)amino,  $N,N$ -( $C_{1-6}$ alkyl) $_2$ amino,  $C_{1-6}$ alkanoylamino,  $N$ -( $C_{1-6}$ alkyl)carbamoyl,  $N,N$ -( $C_{1-6}$ alkyl) $_2$ carbamoyl,  $C_{1-6}$ alkylS(O) $_a$  wherein  $a$  is 0 to 2,  $C_{1-6}$ alkoxy-carbonyl,  $N$ -( $C_{1-6}$ alkyl)sulphamoyl and  $N,N$ -( $C_{1-6}$ alkyl) $_2$ sulphamoyl;~~

$v$  is 0 [[-5]];

$R^4$  and  $R^7$  are hydrogen;

one of  $R^5$  and  $R^6$  is a group of formula (IA):



**(IA)**

~~$R^4$  and  $R^7$  are hydrogen;~~

the other of  $R^5$  and  $R^6$  is hydrogen or methylthio;

$Z$  is  $-O-$ ;


$R^8$  is hydrogen;

$R^9$  is hydrogen;

$R^{10}$  is selected from cyclohexyl, and phenyl optionally substituted ~~on carbon~~ by one or more substituents ~~selected from  $R^{28}$ ;~~

$R^{11}$  is ~~selected from hydrogen,  $C_{1-4}$ alkyl, carbocyclyl or heterocyclyl optionally substituted on carbon by one or more substituents selected from  $R^{28}$ ; and wherein if said heterocyclyl contains an  $-NH-$  moiety, that nitrogen may be optionally substituted by one or more  $R^{29}$ ;~~

$R^{13}$  is a group of formula **(IB)**:



**(IB)**


wherein:

$R^{14}$  is hydrogen;

$R^{15}$  is hydrogen;

$R^{16}$  is hydroxy;

$R^{17}$  is ethyl, ~~wherein  $R^{17}$  is substituted on each carbon of the ethyl group by one substituent selected from  $R^{47}$ , wherein  $R^{47}$  is hydroxyl, or  $R^{17}$  is a group of formula **(IC)**;~~



**(IC)**

wherein:

$R^{18}$  is hydrogen;

$R^{19}$  is hydrogen;

$R^{20}$  is  $C_{1-10}$ alkyl; wherein  $R^{20}$  may be independently optionally substituted on carbon by one or more  $R^{57}$ ; wherein  $R^{57}$  is selected from halo or hydroxyl;

p is 1;

q is 0;

r is 3;

m is 0; wherein the values of  $R^{12}$  may be the same or different;

n is 1;

z is 0-3; wherein the values of  $R^{19}$  may be the same or different;

$R^{21}$  is selected from hydrogen or  $C_{1-6}$ alkyl;

$R^{22}$  and  $R^{23}$  are independently selected from hydrogen, hydroxy, amino, mercapto,  $C_{1-6}$ alkyl,  $C_{1-6}$ alkoxy,  $N(C_{1-6}alkyl)amino$ ,  $N,N(C_{1-6}alkyl)_2amino$ ,  $C_{1-6}alkylS(O)_a$  wherein a is 0 to 2;

$R^{24}$  is hydrogen; and

$R^{25}$  is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl,  $C_{1-4}$ alkyl,  $C_{2-4}alkenyl$ ,  $C_{2-4}alkynyl$ ,  $C_{1-4}alkoxy$ ,  $C_{1-4}alkanoyl$ ,  $C_{1-4}alkanoyloxy$ ,  $N(C_{1-4}alkyl)amino$ ,  $N,N(C_{1-4}alkyl)_2amino$ ,  $C_{1-4}alkanoylamino$ ,  $N(C_{1-4}alkyl)carbamoyl$ ,  $N,N(C_{1-4}alkyl)_2carbamoyl$ ,  $C_{1-4}alkylS(O)_a$  wherein a is 0 to 2,  $C_{1-4}alkoxycarbonyl$ ,  $N(C_{1-4}alkyl)sulphamoyl$  and  $N,N(C_{1-4}alkyl)_2sulphamoyl$ ; wherein  $R^{25}$  may be independently optionally substituted on carbon by one or more  $R^{67}$ ;

each  $R^{26}$ ,  $R^{28}$ ,  $R^{30}$ ,  $R^{36}$ ,  $R^{41}$ ,  $R^{47}$ ,  $R^{51}$  and  $R^{57}$  are independently is selected from halo, nitro, cyano, hydroxy, amino, carbamoyl, mercapto, sulphamoyl, hydroxyaminocarbonyl,  $C_{1-10}alkyl$ ,  $C_{2-10}alkenyl$ ,  $C_{2-10}alkynyl$ , and  $C_{1-10}alkoxy$ ,  $C_{1-10}alkanoyl$ ,  $C_{1-10}alkanoyloxy$ ,  $C_{1-10}alkoxycarbonyl$ ,  $N(C_{1-10}alkyl)amino$ ,  $N,N(C_{1-10}alkyl)_2amino$ ,  $N,N,N(C_{1-10}alkyl)_3ammonio$ ,  $C_{1-10}alkanoylamino$ ,  $N(C_{1-10}alkyl)carbamoyl$ ,  $N,N(C_{1-10}alkyl)_2carbamoyl$ ,  $C_{1-10}alkylS(O)_a$  wherein a is 0 to 2,  $N(C_{1-10}alkyl)sulphamoyl$ ,  $N,N(C_{1-10}alkyl)_2sulphamoyl$ ,  $N(C_{1-10}alkyl)sulphamoylamino$ ,  $N,N(C_{1-10}alkyl)_2sulphamoylamino$ ,  $C_{1-10}alkoxycarbonylamino$ , carbocyclyl, carbocyclyl $C_{1-10}alkyl$ , heterocyclic group, heterocyclyl $C_{1-10}alkyl$ , carbocyclyl $(C_{1-10}alkylene)_e$ - $R^{59}$ -( $C_{1-10}alkylene)_f$ - or heterocyclyl $(C_{1-10}alkylene)_g$ - $R^{60}$ -( $C_{1-10}alkylene)_h$ -; wherein  $R^{26}$ ,  $R^{28}$ ,  $R^{30}$ ,  $R^{36}$ ,  $R^{41}$ ,  $R^{47}$ ,  $R^{51}$  and  $R^{57}$  may be independently optionally substituted on carbon by one or more  $R^{63}$ ; and

wherein if said heterocyclyl contains an ~~NH~~ group, that nitrogen may be optionally substituted by a group selected from  $R^{64}$ ;

$R^{27}$ ,  $R^{29}$ ,  $R^{31}$ ,  $R^{37}$ ,  $R^{42}$ ,  $R^{48}$ ,  $R^{52}$ ,  $R^{58}$  and  $R^{64}$  are independently is selected from  $C_{1-6}$ alkyl,  $C_{1-6}$ alkanoyl,  $C_{1-6}$ alkylsulphonyl, sulphamoyl,  $N$ -( $C_{1-6}$ alkyl)sulphamoyl,  $N,N$ -( $C_{1-6}$ alkyl)<sub>2</sub>sulphamoyl,  $C_{1-6}$ alkoxycarbonyl, carbamoyl,  $N$ -( $C_{1-6}$ alkyl)carbamoyl,  $N,N$ -( $C_{1-6}$ alkyl)<sub>2</sub>carbamoyl, benzyl, phenethyl, benzoyl, phenylsulphonyl and phenyl;

$R^{32}$ ,  $R^{33}$ ,  $R^{43}$ ,  $R^{44}$ ,  $R^{53}$ ,  $R^{54}$ ,  $R^{59}$  and  $R^{60}$  are independently selected from  $O$ ,  $NR^{65}$ ,  $S(O)_x$ ,  $NR^{65}C(O)NR^{66}$ ,  $NR^{65}C(S)NR^{66}$ ,  $OC(O)N=C$ ,  $NR^{65}C(O)$  or  $C(O)NR^{65}$ ; wherein  $R^{65}$  and  $R^{66}$  are independently selected from hydrogen or  $C_{1-6}$ alkyl, and  $x$  is 0-2;

$R^{63}$  and  $R^{67}$  re independently selected from halo, hydroxy, cyano, carbamoyl, ureido, amino, nitro, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, methyl, ethyl, methoxy, ethoxy, vinyl, allyl, ethynyl, methoxycarbonyl, formyl, acetyl, formamido, acetylamino, acetoxymethyl, dimethylamino,  $N$ -methylecarbamoyl,  $N,N$ -dimethylecarbamoyl, methylthio, methylsulphinyl, mesyl,  $N$ -methylsulphamoyl and  $N,N$ -dimethylsulphamoyl; and

~~e, f, g and h~~ are independently selected from 0-2;

or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester or amide thereof.

2. - 3. (Cancelled)

4. (Cancelled)

5. (Cancelled)

6. (Currently Amended) A compound of formula **(I)** according to claim 1 wherein one of  $R^1$  and  $R^2$  is  $C_{1-4}$ alkyl; or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester or amide thereof.


7. (Cancelled)

8. – 11. (Cancelled)

12. (Currently amended) A compound ~~[[of]] having formula (I) according to claim 1 selected from:~~ (+/-)-trans-1,1-dioxo-3-ethyl-3-butyl-5-phenyl-7-methylthio-8-(*N*-{(R)- $\alpha$ -[*N'*-(2-(S)-3-(R)-4-(R)-5-(R)-2,3,4,5,6-pentahydroxyhexyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,4-benzothiazepine[;]), or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester or amide thereof.


13. (Withdrawn – previously presented) A process for preparing a compound of formula (I) or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester or amide thereof, as claimed in claim 1, which process comprises of:

*Process 1*): for compounds of formula (I); reacting a compound of formula (IIa):



(IIa)


with a compound of formula (III):



(III)


wherein L is a displaceable group;

*Process 2):* reacting an acid of formula (IVa):




(IVa)

with an amine of formula (V):




(V);

*Process 3):* for compounds of formula (I) wherein R<sup>13</sup> is a group of formula (IB); reacting an acid of formula (VIa):




(VIa)

with an amine of formula (VI):



(VI); or

*Process 4)* for compounds of formula **(I)** wherein R<sup>6</sup> is methylthio ; reacting a compound of formula **(Xb)**:



**(Xb)**

wherein L is a displaceable group; with a thiol of formula **(XI)**:



**(XI)**

wherein R<sup>m</sup> is methylthio;

and optionally:

- i) converting a compound of the formula **(I)** into another compound of the formula **(I)**;
- ii) removing any protecting groups;
- iii) forming a pharmaceutically acceptable salt or a prodrug.

14. – 17. (Cancelled)

18. (Previously Presented) A pharmaceutical composition which comprises a compound of formula **(I)**, or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester or amide prodrug thereof, as claimed in claim 1 in association with a pharmaceutically-acceptable diluent or carrier.

19. – 25. (Cancelled)